论文部分内容阅读
目的:为了比较培美曲塞与吉西他滨治疗非小细胞肺癌晚期患者的临床疗效。方法:总结非小细胞肺癌晚期患者40例资料。结果:观察组治疗后完全缓解0例,部分缓解6例,稳定10例,总有效率30%,两组疗效结果具有一致性(P>0.05),并发症方面:观察组患者不良反应严重程度(III级与IV级不良反应)明显低于对照组(P<0.05),生活质量评分情况方面:治疗后两组患者生活质量均获不同程度改善,两组得分无统计学差异(P>0.05)。结论:培美曲塞与吉西他滨两组方案治疗非小细胞肺癌晚期患者具有类似的疗效,而培美曲塞治疗方案同时具有较低的不良反应。
OBJECTIVE: To compare the clinical efficacy of pemetrexed and gemcitabine in the treatment of advanced non-small cell lung cancer patients. Methods: To summarize 40 cases of advanced non-small cell lung cancer patients. Results: In the observation group, complete remission was observed in 0 cases, partial remission in 6 cases, stable in 10 cases and total effective rate of 30%. There was concordance between the two groups (P> 0.05). Complications: The severity of adverse reactions (Grade III and IV adverse reactions) were significantly lower than those in the control group (P <0.05). In terms of quality of life score, the quality of life of both groups improved to some extent after treatment, with no significant difference between the two groups (P> 0.05 ). CONCLUSION: Pemetrexed and gemcitabine have similar efficacy in the treatment of advanced non-small cell lung cancer patients, while pemetrexed treatment regimen also has lower adverse reactions.